Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Subscribe to see Anbio Biotechnology’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Anbio Biotechnology is a biotech company headquartered in Frankfurt am Main, Germany. It is publicly listed (NNNN) with a market capitalisation of $215.1M. Xcout tracks 7 named people at Anbio Biotechnology, including Michael Lau (Chief Executive Officer).
1 more named person on record for Anbio Biotechnology, with roles, board committees and tenure — see the full roster →
A few of Anbio Biotechnology's closest competitors — see the full list of competitors and alternatives →
Hangzhou Biotest Biotech Co., LTD. is an enterprise focused on the research, development, manufacturing, sales, and servicing of in vitro diagnostic (IVD) solutions. Operating both domestically within China and across international markets, the company provides a comprehensive range of medical testing products. Their offerings span crucial health areas including reproductive health, cancer detection, cardiovascular conditions, inflammatory markers, biochemical analysis, and various infectious diseases. This extensive portfolio also encompasses rapid diagnostic tests for COVID-19 (covering both antibody and antigen detection), as well as screening kits for drug use (utilizing urine, saliva, and hair samples) and assessing vitamin D levels. Beyond diagnostic kits and reagents, Hangzhou Biotest Biotech also supplies essential accompanying equipment, such as immunochromatography readers and fluorescence immunoassay quantitative analyzers. The company, established in 2008, is based in Hangzhou, China.
HUMAN Diagnostics Worldwide is a German manufacturer and supplier of in vitro diagnostic equipment, reagents, and laboratory solutions for clinical diagnostics.
GNA Biosolutions GmbH is a German biotechnology company developing rapid molecular-diagnostics systems, including instruments and consumables for automated nucleic-acid extraction and amplification. Its solutions are intended for applications such as clinical testing, research, and other settings requiring fast pathogen or genetic analysis.
Getein Biotech, Inc. is an enterprise primarily focused on the research, development, manufacturing, and global distribution of in vitro diagnostic (IVD) solutions. Founded in 2002 and based in Nanjing, China, the company offers a comprehensive array of diagnostic products. This includes a variety of diagnostic reagents, advanced analytical instruments, and crucial calibrators. Getein also supplies foundational raw materials for reagents, such as monoclonal and polyclonal antibodies, antigens, antiserum, and microspheres. Its extensive product line caters to diverse medical fields, encompassing diagnostics for cardiac markers, inflammatory conditions, renal function, blood coagulation, thyroid disorders, fertility assessments, diabetes care, and thrombus detection. These offerings broadly serve applications in cardiovascular, inflammatory, diabetes, reproductive, renal, hepatic, and other key health areas.
Sansure Biotech Inc., founded in Changsha, China, in 2008, is dedicated to the global development and commercialization of advanced diagnostic and research products. The company offers a diverse range of solutions, including upstream nucleic acid extraction kits, real-time PCR systems for both clinical and investigative purposes, and fluorescence detection platforms. Their extensive product portfolio encompasses diagnostic assays for critical conditions like the novel coronavirus, viral hepatitis, and AIDS. Furthermore, they provide blood screening and general extraction kits, tests for cancer-related biomarkers, and solutions for respiratory, sexually transmitted, digestive tract, prenatal, postnatal, and genetic diseases. Sansure Biotech also supplies essential laboratory instrumentation and various consumables, primarily serving hospitals and scientific laboratories worldwide.
Abnova (Taiwan) Corporation specializes in the development and distribution of a comprehensive range of recombinant proteins and antibodies. The company's extensive product portfolio caters to diverse research and diagnostic applications, featuring specialized reagents for SARS-CoV/CoV-2, nucleic acids (both DNA and RNA), and various proteins and peptides. Their offerings further include items like DNAxPab, laboratory beads, dyes, cellular lysates, microscopic slides, antibody pairs and associated kits, as well as antibody and tissue arrays. Additionally, they provide in situ hybridization products, advanced laboratory systems and automation, GMP-grade and analyte-specific reagents, and solutions for in vitro diagnostics. Beyond these product lines, Abnova supplies a broad spectrum of antibody types, such as MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and those specifically targeting circulating rare cells. The company also delivers integrated solutions and services, encompassing gene synthesis and cytogenetic analysis, peptide services, protein expression and conjugations, custom antibody generation, and assay development. Abnova (Taiwan) Corporation operates from its headquarters in Taipei, Taiwan.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.